Register Login

PROTAGONIST THERAPEUTICS, INC (PTGX)

Director PATEL DINESH V PH D 🟡 adjusted position in 100.0K shares (2 derivative) of Protagonist Therapeutics, Inc (PTGX) at $149.11 ($19.2M) Transaction Date: Aug 10, 2026 | Filing ID: 095111

Full text
Register to leave comments
  • News bot Aug. 12, 2026, 10:43 p.m.

    🔍 PATEL DINESH V PH D (Director)

    Company: Protagonist Therapeutics, Inc (PTGX)

    Report Date: 2026-08-10

    Transaction Summary:

    • Total transactions: 6
    • Derivative instruments: 2
    • Holdings reported: 0
    • Total shares acquired: 100,000
    • Total shares sold: 200,000

    Detailed Transactions and Holdings:

    • Acquired 65,761 shares of Common Stock at $21.58 per share (Direct)
      Date: 2026-08-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 589,239.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 65,761 shares of Common Stock at $149.11 per share (Direct)
      Date: 2026-08-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 523,478.00 | transaction_form_type: 4 | Footnotes: F2
    • Acquired 34,239 shares of Common Stock at $21.58 per share (Direct)
      Date: 2026-08-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 557,717.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 34,239 shares of Common Stock at $148.52 per share (Direct)
      Date: 2026-08-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 523,478.00 | transaction_form_type: 4 | Footnotes: F3
    • Sold 65,761 shares of Stock Option (right to buy) at $21.58 per share (Derivative)
      Date: 2026-08-10 | Code: M | Expires: 2026-10-11 | equity_swap_involved: 0 | shares_owned_after: 159,239.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 34,239 shares of Stock Option (right to buy) at $21.58 per share (Derivative)
      Date: 2026-08-11 | Code: M | Expires: 2026-10-11 | equity_swap_involved: 0 | shares_owned_after: 125,000.00 | transaction_form_type: 4 | Footnotes: F1

    Footnotes:

    • F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on January 30, 2026. The 10b5-1 plan provides for the exercise of fully vested stock options that expire on October 11, 2026, and the sale of shares of common stock acquired upon exercise of the stock options.
    • F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.41 to $151.29. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
    • F3: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $147.64 to $151.30. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Search

News categories